Affidea has acquired NU-MED Group from Enterprise Investors, enhancing its oncology service capabilities in Poland.

Target Information

NU-MED Group, a reputable healthcare provider based in Poland, specializes in comprehensive oncological treatments, including radiotherapy, brachytherapy, and chemotherapy. With over 17 years of experience in the healthcare sector, NU-MED operates four specialized medical facilities dedicated to diagnosing and treating cancer patients. This acquisition significantly enhances Affidea's service offerings in Poland, allowing it to provide an integrated range of cancer care services.

Industry Overview in Poland

The healthcare industry in Poland has been growing steadily, driven by increasing demand for quality medical services and technological advancements. The Polish healthcare system combines both public and private sectors, with ongoing reforms aimed at improving patient outcomes and expanding access to healthcare services.

Recent statistics indicate a surge in investment in healthcare facilities and innovation, particularly in specialized services like oncology, which remains a critical focus area

View Source

Similar Deals

Trigon Bioceltix S.A.

2025

Other Veterinary Drugs Poland
Trigon Scope Fluidics S.A.

2025

Other Bio Diagnostics & Testing Poland
Urgo Sp. z o. o. MyBestPharm S.A.

2025

Other Pharmaceuticals (NEC) Poland
Penta Hospitals Poland NZOZ Pasternik

2025

Other Residential & Long-Term Care Poland
Polmed S.A. Kliniki Neuroradiochirurgii

2024

Other Hospitals, Clinics & Primary Care Services Poland
Polmed Diagnostyka Grupa Medicus

2023

Other Medical & Diagnostic Laboratories Poland

Affidea

invested in

NU-MED Group

in 2024

in a Other deal

Deal Parameters
Industry
Country
Seller type

Sign Up to Dealert